Related Experiment Video

Updated: Jun 18, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex

Charles Craddock1, James Anson, Patrick Chu

  • 1Queen Elizabeth Hospital, Birmingham, UK. Charles.Craddock@uhb.nhs.uk

Expert Opinion on Drug Safety
|December 2, 2009
PubMed
Abstract

Insights

Amphotericin B lipid complex (ABLC) is effective against fungal infections with reduced nephrotoxicity. However, managing infusion-related reactions is crucial for patient care and requires improved strategies.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Amphotericin B lipid complex (ABLC) is a key antifungal agent with broad-spectrum activity.
  • ABLC offers reduced nephrotoxicity compared to conventional amphotericin B.
  • Infusion-related reactions remain a concern despite ABLC's improved safety profile.

Purpose of the Study:

  • To review strategies for mitigating drug delivery reactions associated with ABLC.
  • To provide guidance on managing adverse events during ABLC therapy.
  • To address the preservation of renal function and management of elevated creatinine levels.

Main Methods:

  • Review of published evidence on ABLC adverse event management.
  • Synthesis of clinical experience from multiple healthcare centers.
  • Focus on strategies to prevent and manage infusion-related reactions.

Main Results:

  • Guidance for healthcare professionals on managing ABLC adverse events.
  • Evidence-based recommendations for effective reaction management.
  • Strategies for preserving renal function during ABLC treatment.

Conclusions:

  • Amphotericin B lipid complex is a valuable antifungal treatment.
  • Enhanced strategies for managing infusion-related adverse events are necessary.
  • Effective management of ABLC adverse events is critical for optimal patient outcomes.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...